Search research articles
Contact Us
Filters
Showing results (1-10 of 28) with videos related to
Page
of 3
Sort By:
Immunotherapy
|
March 6, 2018
Tocilizumab in the treatment of giant cell arteritis
Nicolai Leuchten, Martin Aringer
Zeitschrift Fur Rheumatologie
|
May 15, 2023
[Assessment tools for systemic lupus erythematosus]
Martin Aringer, Nicolai Leuchten
Rheumatic Diseases Clinics of North America
|
October 1, 2019
Treat to Target in Systemic Lupus Erythematosus
Martin Aringer, Nicolai Leuchten, Matthias Schneider
Rheumatology (Oxford, England)
|
December 30, 2021
Erratum to: Glucocorticoid dosing and relapses in giant cell arteritis-a single centre cohort study
Laura Felten, Nicolai Leuchten, Martin Aringer
Rheumatology (Oxford, England)
|
September 6, 2021
Glucocorticoid dosing and relapses in giant cell arteritis-a single centre cohort study
Laura Felten, Nicolai Leuchten, Martin Aringer
Rheumatology (Oxford, England)
|
January 24, 2026
Treating-to-target: remission and low disease activity in systemic lupus erythematosus versus rheumatoid arthritis
Konrad Hüther, Nicolai Leuchten, Martin Aringer
Clinical and Experimental Rheumatology
|
September 14, 2023
Physical exercise is associated with less fatigue, less pain and better sleep in patients with systemic lupus erythematosus
Helena Wohland, Martin Aringer, Nicolai Leuchten
Current Rheumatology Reports
|
May 15, 2020
New Criteria for Lupus
Martin Aringer, Nicolai Leuchten, Sindhu R Johnson
Annals of the Rheumatic Diseases
|
February 6, 2026
Belimumab induces early and sustained resolution of lupus arthritis
Nicolai Leuchten, Ioannis Parodis, Ralph Brinks, et al.
Rheumatology (Oxford, England)
|
May 27, 2025
Interleukin-6 receptor blockade leads to low fibrinogen values as part of their effects on the acute phase
Martin Achleitner, Oliver Tiebel, Nicolai Leuchten, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 28) with videos related to
Sort By:
Page
of 3
Immunotherapy
|
March 6, 2018
Tocilizumab in the treatment of giant cell arteritis
Nicolai Leuchten, Martin Aringer
Zeitschrift Fur Rheumatologie
|
May 15, 2023
[Assessment tools for systemic lupus erythematosus]
Martin Aringer, Nicolai Leuchten
Rheumatic Diseases Clinics of North America
|
October 1, 2019
Treat to Target in Systemic Lupus Erythematosus
Martin Aringer, Nicolai Leuchten, Matthias Schneider
Rheumatology (Oxford, England)
|
December 30, 2021
Erratum to: Glucocorticoid dosing and relapses in giant cell arteritis-a single centre cohort study
Laura Felten, Nicolai Leuchten, Martin Aringer
Rheumatology (Oxford, England)
|
September 6, 2021
Glucocorticoid dosing and relapses in giant cell arteritis-a single centre cohort study
Laura Felten, Nicolai Leuchten, Martin Aringer
Rheumatology (Oxford, England)
|
January 24, 2026
Treating-to-target: remission and low disease activity in systemic lupus erythematosus versus rheumatoid arthritis
Konrad Hüther, Nicolai Leuchten, Martin Aringer
Clinical and Experimental Rheumatology
|
September 14, 2023
Physical exercise is associated with less fatigue, less pain and better sleep in patients with systemic lupus erythematosus
Helena Wohland, Martin Aringer, Nicolai Leuchten
Current Rheumatology Reports
|
May 15, 2020
New Criteria for Lupus
Martin Aringer, Nicolai Leuchten, Sindhu R Johnson
Annals of the Rheumatic Diseases
|
February 6, 2026
Belimumab induces early and sustained resolution of lupus arthritis
Nicolai Leuchten, Ioannis Parodis, Ralph Brinks, et al.
Rheumatology (Oxford, England)
|
May 27, 2025
Interleukin-6 receptor blockade leads to low fibrinogen values as part of their effects on the acute phase
Martin Achleitner, Oliver Tiebel, Nicolai Leuchten, et al.
Page
of 3